Board of Directors

  • cgoddard

  • Colin Goddard, Ph.D.
    Chairman & CEO

    Colin Goddard serves as Chairman & CEO of BlinkBio Inc. having joined the company as an angel investor and executive chairman in 2011. Dr. Goddard is actively involved as an investor, executive and board member in a number of early stage biotechnology companies, leveraging over 25 years of experience in the industry. From October 1998, until its $4 billion acquisition by Astellas Pharmaceuticals, Inc. in June of 2010, Dr. Goddard was CEO of OSI Pharmaceuticals, Inc. a company he joined as a scientist in 1989. In this role he raised over $1.5 billion and oversaw the development, approval and commercial launch of Tarceva®, a leading lung cancer medicine. He is Chairman of the Board of Mission Therapeutics and a member of the board of Endocyte (NASDAQ: ECYT), and has been active in many organizations that promote the advancement of cancer treatment and awareness, science education and the biotechnology industry. He received his PhD in Cancer Pharmacology in the UK in1985 and conducted his post-doctoral research at the National Cancer Institute in Bethesda, MD.

  • gsmith

  • Geoff Smith

    Geoffrey W. Smith is a Co-Founder and Managing Partner of Ascent Biomedical Ventures, a venture capital fund focused on early-stage life sciences investments. He has been an active founder, manager, and investor in healthcare and technology companies since 1995. He currently serves on the Board of Directors of Azevan Pharmaceuticals, BackBeat Medical, Biomerix, Caliber Therapeutics, BlinkBio, and Vivasure Medical. Mr. Smith received a B.A. (with honors) from Williams College and a J.D. from the University of Pennsylvania Law School.

  • mgargano

  • Michael Gargano

    Michael Gargano joined the BlinkBio board in 2009 as a founder of the Company and continues to serve as the representative of the Series A investors. Michael is a Managing Director at Argent Ventures LLC, where he is responsible for structuring and financing new acquisitions and for overseeing development, leasing and management of the firm’s properties. Prior to joining Argent, Mr. Gargano was a real estate attorney with the law firm of Shearman & Sterling, where he represented institutional and government clients on major real estate development and financing transactions. He is Chairman of the Board of iCareDx, a diagnostics company. He is a member of the Board of Directors of the Fund for Public Health – NY, the Hollywood Chamber of Commerce and the Hollywood Property Owners Alliance. Mr. Gargano earned a B.A. from the State University of New York at Stony Brook and a J.D. from Boston University.

  • vmehta


  • Viren Mehta, PharmD, MBA

    Viren Mehta founded and is managing member of Mehta Partners, LLC. His analytical insights on global health care have influenced bio-pharmaceutical strategy and investments worldwide. Educated at the University of Southern California (Doctor of Pharmacy) and UCLA (MBA in international finance and marketing), he has worked with senior BioPharma leaders and investment managers for over 30 years. Viren’s biopharma strategic advisory work focuses on refining the business model to expand global healthcare access, and to help the bio-pharmaceutical industry succeed globally. Viren’s philanthropic work in ecology and education through viram foundation includes an active board role with Project Hope (Washington DC) and the Venice Family Clinic (Los Angeles, CA). Viren began with Merck & Co. in international strategic planning and competitor analysis. This foundation prompted Wood MacKenzie & Company Inc. to invite him to establish a pharmaceutical research function in New York. This effort was expanded at S.G. Warburg & Company, and led to the formation of the BioPharma investment advisory group Mehta and Isaly. Now known as Mehta Partners, with a 30-year record, Viren continues to focus on helping refine investment strategy to achieve superior growth while enhancing access to healthcare innovations.